Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06254391
Status:
RECRUITING
Last Update Posted:
2024-02-12
First Post:
2024-02-02
Brief Title:
Aspirin Dose Comparison in Elderly PCI Patients 30mg vs 75mg in Acute Coronary Syndrome
Sponsor:
Medical University of Warsaw
Organization:
Medical University of Warsaw
Study Overview
Official Title:
Very Low-dose Aspirin 30mg vs Standard Low-dose Aspirin 75mg Among Patients Aged 65 Years or Above Undergoing PCI for Acute Coronary Syndrome an Open-label Randomized Crossover Design Trial
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LowASA-PCI
Brief Summary:
Elderly patients undergoing percutaneous coronary intervention PCI face a high risk of both ischemic and hemorrhagic complications necessitating antiplatelet therapy Previous data indicate that even at a dose of 20-30 mgday aspirin ASA allows almost complete inhibition of thromboxane TX A2 biosynthesis in healthy volunteers However ASA at a dose of 30 mgday has not been evaluated in the acute phase of myocardial infarction or among elderly patients where it may achieve an optimal balance between bleeding risk and ischemic complications
This randomized study will include 40 patients over 65 years undergoing PCI for acute coronary syndrome ACS It compares a new dual antiplatelet therapy DAPT strategy consisting of a P2Y12 antagonist ticagrelor and ASA at a very low dose of 30 mgday n20 against the current standard treatment P2Y12 antagonist and ASA at a dose of 75 mg n20 in the control group
This randomized study will include 40 patients over 65 years undergoing PCI for acute coronary syndrome ACS It compares a new dual antiplatelet therapy DAPT strategy consisting of a P2Y12 antagonist ticagrelor and ASA at a very low dose of 30 mgday n20 against the current standard treatment P2Y12 antagonist and ASA at a dose of 75 mg n20 in the control group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None